海尔生物
(688139)
| 流通市值：101.87亿 | | | 总市值：101.87亿 |
| 流通股本：3.18亿 | | | 总股本：3.18亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,782,020,224.83 | 1,223,284,970.75 | 686,909,061.52 | 2,280,896,019.23 |
| 营业收入 | 1,782,020,224.83 | 1,223,284,970.75 | 686,909,061.52 | 2,280,896,019.23 |
| 二、营业总成本 | 1,468,536,204.53 | 979,179,228.79 | 538,737,974.7 | 1,966,937,346.46 |
| 营业成本 | 917,519,524.02 | 632,770,459.32 | 346,205,232.18 | 1,125,977,841.74 |
| 税金及附加 | 15,744,301.58 | 11,107,409.56 | 5,757,824.8 | 20,814,451.67 |
| 销售费用 | 211,737,388.26 | 136,298,159.37 | 80,476,077.76 | 339,573,972.29 |
| 管理费用 | 133,850,540.5 | 83,823,829.1 | 41,044,822.78 | 183,467,514.04 |
| 研发费用 | 223,579,922.81 | 143,448,942.59 | 77,257,984.27 | 320,636,061.79 |
| 财务费用 | -33,895,472.64 | -28,269,571.15 | -12,003,967.09 | -23,532,495.07 |
| 其中:利息费用 | 2,470,544.38 | 1,758,321.4 | 842,633.79 | 3,511,618.34 |
| 其中:利息收入 | 37,578,315.51 | 28,268,836.6 | 13,038,215.13 | 35,609,318.83 |
| 加:公允价值变动收益 | -172,721 | -1,139,396.68 | 334,520 | 2,055,633.22 |
| 加:投资收益 | 16,606,073.73 | 11,307,110.66 | 3,291,655.49 | 83,033,401.63 |
| 资产处置收益 | -124,596.66 | -130,256.06 | -81,512.41 | -1,599,128.48 |
| 资产减值损失(新) | -1,755,038.72 | -1,728,897.13 | -12,496.58 | -1,642,752.84 |
| 信用减值损失(新) | -19,364,586.03 | -15,489,684.14 | -6,728,018.99 | -2,418,299.47 |
| 其他收益 | 32,131,652.64 | 19,865,772.08 | 9,301,428.65 | 45,013,812.56 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 340,804,804.26 | 256,790,390.69 | 154,276,662.98 | 438,401,339.39 |
| 加:营业外收入 | 2,970,937.9 | 2,095,775.24 | 446,140.86 | 3,341,881.01 |
| 减:营业外支出 | 1,357,245.63 | 17,278.86 | 21,412.15 | 7,252,010.97 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 342,418,496.53 | 258,868,887.07 | 154,701,391.69 | 434,491,209.43 |
| 减:所得税费用 | 23,440,550.64 | 19,731,759.14 | 12,849,152.72 | 22,432,550.67 |
| 六、净利润 | 318,977,945.89 | 239,137,127.93 | 141,852,238.97 | 412,058,658.76 |
| 持续经营净利润 | 318,977,945.89 | 239,137,127.93 | 141,852,238.97 | 412,058,658.76 |
| 归属于母公司股东的净利润 | 309,141,846.32 | 234,342,835.01 | 137,614,697.49 | 406,073,643.93 |
| 少数股东损益 | 9,836,099.57 | 4,794,292.92 | 4,237,541.48 | 5,985,014.83 |
| (一)基本每股收益 | 0.98 | 0.74 | 0.44 | 1.28 |
| (二)稀释每股收益 | 0.98 | 0.74 | 0.44 | 1.28 |
| 八、其他综合收益 | -23,664,262.3 | -24,452,127.42 | 12,754.54 | -43,521,492.11 |
| 归属于母公司股东的其他综合收益 | -23,664,262.3 | -24,452,127.42 | 12,754.54 | -43,521,492.11 |
| 九、综合收益总额 | 295,313,683.59 | 214,685,000.51 | 141,864,993.51 | 368,537,166.65 |
| 归属于母公司股东的综合收益总额 | 285,477,584.02 | 209,890,707.59 | 137,627,452.03 | 362,552,151.82 |
| 归属于少数股东的综合收益总额 | 9,836,099.57 | 4,794,292.92 | 4,237,541.48 | 5,985,014.83 |
| 公告日期 | 2024-10-30 | 2024-08-23 | 2024-04-26 | 2024-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |